Clinical use of blood, blood components and blood products.
The goal of modern transfusion therapy is to provide appropriate replacement therapy with blood components as opposed to whole blood for patients with specific hematologic deficiencies. A prerequisite of component therapy is, therefore, correct identification of the deficiency. Appropriate use of components avoids many of the hazards associated with the use of whole blood, and at the same time makes maximal use of this valuable resource. Blood components separated from whole blood soon after collection and appropriately stored can, in combination, provide all the factors present in fresh whole blood. Red cell concentrates prepared from multiple packs have a hematocrit of approximately 70%. They may be stored for up to 3 weeks at 4 degrees C and are recommended for most situations requiring red cell transfusions. Platelet concentrates, which can be stored for up to 72 hours at 22 degrees C, may be used for thrombocytopenic patients. Fresh frozen plasma, stored plasma, cryoprecipitated factor VIII, factor VIII concentrate and factor IX complex concentrate are available for the proper treatment of patients with hemorrhagic disorders due to coagulation factor deficiencies. Similarly, albumin and immune serum globulin are available for their oncotic and antibody properties respectively. Thus, the availability and appropriate use of the various blood products allows not only optimal transfusion therapy for each patient, but also fuller utilization of national blood resources.
D000418:Albumins / Q000627:therapeutic use; D001793:Blood Preservation / Q000379:methods; D001800:Blood Specimen Collection / Q000379:methods; D001803:Blood Transfusion; D017707:Erythrocyte Transfusion; D005169:Factor VIII / Q000627:therapeutic use; D005612:Freeze Drying / Q000379:methods; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D017713:Platelet Transfusion
D000418:Albumins; D005169:Factor VIII